Ameriprise
CYTK icon

Ameriprise’s Cytokinetics CYTK Stock Holding History

Ameriprise’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12M Buy
+181,700
New +$11.5M ﹤0.01% 1791

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise's CYTK Position: Q1 2026 in Review

Ameriprise reduced its Cytokinetics (CYTK) stake by 45% in Q1 2026, selling an estimated $15.4M and leaving 302,802 shares worth $20M. The position accounts for ﹤0.01% of the portfolio, ranked #1409.

Ameriprise first reported a position in CYTK in Q2 2013 and has held it in 43 quarters since. The position peaked at $35.4M in Q4 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Ameriprise held 302,802 shares of Cytokinetics worth $20M as of Q1 2026.
  • Ameriprise sold 243,003 Cytokinetics shares in Q1 2026, an estimated $15.4M.
  • Cytokinetics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #1409 holding.
  • Ameriprise first reported a position in Cytokinetics in Q2 2013 and has held it in 43 quarters since.
  • Ameriprise's Cytokinetics position peaked at $35.4M in Q4 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.